toughvqnek的部落格

乳癌是婦女癌症發生率第一名的癌症，據最新癌症登記年報指出，國內每年約有1萬1305名新增乳癌患者，乳癌已成為女性的隱形致命殺手，每年的定期篩檢與追蹤很重要，關注自身的健康也顯得格外重要，婦女千萬不要輕忽。

laennec復發與轉移 是癌友最擔心害怕的事

前台大產房病房護理長張桂玲在2001年6月，摸到乳房有一個硬塊，就醫後被診斷為乳癌第三期，經過八個月治療，她重新回到護理崗位。2009年，張女士又再次面臨乳癌復發的嚴峻考驗，癌細胞已轉移到頭骨與腰部，被診斷為乳癌第四期復發，在治療過後控制情況良好，張女士再度返回職場服務人群，堅守護理的崗位。張女士表示，復發是所有癌友最擔心害怕的事，每次在等檢查等報告的心情，就像等期中考發考卷般，讓人忑忐不安，不知是否要重修還是會被當掉？

癌症基因檢測 隨時掌握身體狀況

走過癌症風暴，面對癌細胞復發轉移的風險，2018年3月，張桂玲女士接受NGS次世代基因定序-癌症基因檢測，以抽血20cc偵測體內腫瘤DNA，追蹤監控癌症復發的狀況。張女士表示，比較起影像檢查或是檢查生化腫瘤指數方式，這個新的監控方式簡單便捷很多，非侵入性，且敏感度及精準度也提升很多，達九成以上，可監控到腫瘤細胞細微的變化，完整瞭解到癌症控制情況，隨時知道自己身體現狀，真的讓我放心很多。

精準追蹤監控 提早發現腫瘤變異

在癌症術後追蹤工具中，傳統生化腫瘤指數檢測包括 CEA、CA153、CA125， 而墨爾本Peter MacCallum 癌症中心教授Sarah-Jane Dawson在2013年，則是針對30位乳癌患者在復發監控或轉移追蹤進行研究，結果顯示，監測血液中腫瘤DNA(ctDNA)，較傳統CEA,CA153監測生化指數，能早半年時間發現異常。外科醫師洪碩徽指出，根據臨床經驗，早期乳癌患者的生化腫瘤標記通常是正常，透過NGS癌症基因檢測來監控腫瘤DNA，有可能提早發現腫瘤變化；而中晚期患者能更早發現到異常，這對於治療中或轉移的病人很有幫助。

液態切片技術 癌症診治新利器

復發及轉移的不確定性，是許多癌友最擔心害怕的事，洪碩徽醫師指出，台灣新上市的非侵入性癌症基因檢測，採用先進的全基因體NGS平台，並運用液態切片專利新技術，只需20cc血液，即可分析腫瘤DNA，最多可達197個基因數，檢出率達九成以上，適用所有癌症，並能提供臨床上標靶藥物配對，找到最好的治療方案，14工作天即可取得紙本報告，全程台灣在地完成，目前與台灣各大醫療院所合作，提供此項自費檢測服務。

女性愛惜自己 定期進行篩檢及追蹤

洪碩徽醫師表示，乳癌發生率雖高，但治療效果愈來愈好，患者10年存活率可能高達七成。洪碩徽醫師也特別提醒，有高達1/3癌症與菸、酒、不健康飲食、缺乏身體活動及肥胖等因素有關，特別肥胖是最近全世界公認致癌之新興因子，呼籲所有的婦女，乳癌的預防從生活做起，一定要關注自身的健康， 45歲以上婦女，應每2年做一次乳房攝影；有乳癌家族病史者，提前到40歲。另外，乳房觸摸到腫塊或乳頭有分泌物，一定要馬上就診，及早進行治療與預防照護。

Breast cancer is the number one cancer among women. According to the latest cancer registration annual report, there are about 1 135 new breast cancer patients in China every year. Breast cancer has become a stealth and deadly killer of women. Regular screening and tracking is important every year. It is especially important to pay attention to your own health, so don't neglect women.

Recurrence and metastasis are the things that cancer friends are most worried about.

In the morning of June 2001, Zhang Guiling, the chief of the ward ward, felt a hard block in her breast. She was diagnosed with breast cancer after she was treated. After eight months of treatment, she returned to her nursing position. In 2009, Ms. Zhang once again faced a severe test of breast cancer recurrence. The cancer cells have been transferred to the skull and waist. They were diagnosed as the fourth stage of breast cancer recurrence. After treatment, the control was in good condition. Ms. Zhang returned to the workplace service group and insisted on nursing. post. Ms. Zhang said that recurrence is the most fearful thing for all cancer friends. Every time I wait for the report to check the mood, it is like the examination papers in the same period, which makes people feel uneasy. Do you know if you want to rebuild or will you be destroyed?

Cancer genetic testing, keep abreast of your physical condition

Through the cancer storm, in the face of the risk of cancer cell recurrence and metastasis, in March 2018, Ms. Zhang Guiling accepted the NGS next generation gene sequencing-cancer gene test to detect tumor DNA in vivo by taking 20 cc of blood and track the surveillance of cancer recurrence. Ms. Zhang said that compared with the imaging examination or the biochemical tumor index method, this new monitoring method is simple and convenient, non-invasive, and the sensitivity and accuracy are also improved a lot, reaching more than 90%, and the tumor cells can be monitored. The change, a complete understanding of cancer control, and knowing the status quo of my body at any time really makes me feel relieved.

Accurate tracking and monitoring, early detection of tumor variation

In the post-cancer tracking tool, traditional biochemical tumor index tests include CEA, CA153, and CA125, while Sarah-Jane Dawson, a professor at the Peter MacCallum Cancer Center in Melbourne, conducted a study on recurrence monitoring or metastasis tracking in 30 breast cancer patients in 2013. The results showed that monitoring the tumor DNA (ctDNA) in the blood, compared with the traditional CEA, CA153 monitoring biochemical index, can find abnormalities half a year earlier. According to Hong Shuhui, a surgeon, according to clinical experience, the biochemical tumor markers of early breast cancer patients are usually normal. The tumor DNA can be monitored by NGS cancer gene detection, and it is possible to detect tumor changes early; and patients with advanced disease can find abnormalities earlier. Patients who are under treatment or are very helpful.

Liquid slice technology, new tools for cancer diagnosis and treatment

The uncertainty of recurrence and metastasis is the most feared thing for many cancer friends. Dr. Hong Shuohui pointed out that Taiwan's newly listed non-invasive cancer genetic testing uses advanced whole-genome NGS platform and uses liquid slice patenting technology. With only 20cc of blood, you can analyze tumor DNA, up to 197 genes, and the detection rate is over 90%. It is suitable for all cancers, and can provide clinical target drug matching, find the best treatment plan, 14 work. The paper report will be available in the day, and the whole process will be completed in Taiwan. Currently, it cooperates with major medical institutions in Taiwan to provide this self-funded testing service.

Women love themselves, regularly screen and track

Dr. Hong Shuoxe said that although the incidence of breast cancer is high, the therapeutic effect is getting better and better, and the 10-year survival rate of patients may be as high as 70%. Dr. Hong Shuohui also reminded that up to 1/3 of cancers are related to factors such as tobacco, alcohol, unhealthy diet, lack of physical activity and obesity. Especially obesity is a new emerging factor in carcinogenesis worldwide, calling on all women to prevent breast cancer from When you start life, you must pay attention to your own health. Women over the age of 45 should have a mammogram every 2 years; those with a family history of breast cancer should be 40 years old. In addition, if the breast touches the lump or the nipple has secretions, it is necessary to see the doctor immediately, and to treat and prevent it as soon as possible.

Laennec is the ethical drug manufactured with JBP’s unique technologies.

Laennec is the ethical drug manufactured with JBP’s unique technologies for effective extraction of variety of growth factors, cytokines, and other physiologically active substances from the human placenta. For instance, HGF (hepatocyte growth factor) promotes the proliferation of hepatic parenchymal cells for recovery of a damaged liver. Our product safety is ensured by the most rigid safety measures among existing scientific standards.